These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 22096404)

  • 1. Antimicrobial therapy for the treatment of opportunistic infections in HIV/AIDS patients: a critical appraisal.
    Seddon J; Bhagani S
    HIV AIDS (Auckl); 2011; 3():19-33. PubMed ID: 22096404
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preventing opportunistic infections in human immunodeficiency virus-infected persons: implications for the developing world.
    Kaplan JE; Hu DJ; Holmes KK; Jaffe HW; Masur H; De Cock KM
    Am J Trop Med Hyg; 1996 Jul; 55(1):1-11. PubMed ID: 8702012
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Treatment and prevention of opportunistic infections].
    Staehelin C; Elzi L; Weber R; Furrer H
    Ther Umsch; 2014 Aug; 71(8):475-82. PubMed ID: 25093312
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence, clinical spectrum, risk factors and impact of HIV-associated immune reconstitution inflammatory syndrome in South Africa.
    Haddow LJ; Moosa MY; Mosam A; Moodley P; Parboosing R; Easterbrook PJ
    PLoS One; 2012; 7(11):e40623. PubMed ID: 23152745
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Surveillance for AIDS-defining opportunistic illnesses, 1992-1997.
    Jones JL; Hanson DL; Dworkin MS; Alderton DL; Fleming PL; Kaplan JE; Ward J
    MMWR CDC Surveill Summ; 1999 Apr; 48(2):1-22. PubMed ID: 12412613
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neurologic complications of HIV-1 infection and its treatment in the era of antiretroviral therapy.
    Kranick SM; Nath A
    Continuum (Minneap Minn); 2012 Dec; 18(6 Infectious Disease):1319-37. PubMed ID: 23221843
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The cost-effectiveness of preventing AIDS-related opportunistic infections.
    Freedberg KA; Scharfstein JA; Seage GR; Losina E; Weinstein MC; Craven DE; Paltiel AD
    JAMA; 1998 Jan; 279(2):130-6. PubMed ID: 9440663
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlates of opportunistic infections in children infected with the human immunodeficiency virus managed before highly active antiretroviral therapy.
    Dankner WM; Lindsey JC; Levin MJ;
    Pediatr Infect Dis J; 2001 Jan; 20(1):40-8. PubMed ID: 11176565
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ocular manifestations of HIV infection.
    Jabs DA
    Trans Am Ophthalmol Soc; 1995; 93():623-83. PubMed ID: 8719695
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and immunologic predictors of death after an acute opportunistic infection: results from ACTG A5164.
    Grant PM; Komarow L; Sanchez A; Sattler FR; Asmuth DM; Pollard RB; Zolopa AR
    HIV Clin Trials; 2014; 15(4):133-9. PubMed ID: 25143022
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HIV-associated opportunistic CNS infections: pathophysiology, diagnosis and treatment.
    Bowen LN; Smith B; Reich D; Quezado M; Nath A
    Nat Rev Neurol; 2016 Oct; 12(11):662-674. PubMed ID: 27786246
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pneumocystis jiroveci pneumonia in adult patients with AIDS: treatment strategies and emerging challenges to antimicrobial therapy.
    Patel N; Koziel H
    Treat Respir Med; 2004; 3(6):381-97. PubMed ID: 15658884
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimal timing for antiretroviral therapy initiation in patients with HIV infection and concurrent cryptococcal meningitis.
    Njei B; Kongnyuy EJ; Kumar S; Okwen MP; Sankar MJ; Mbuagbaw L
    Cochrane Database Syst Rev; 2013 Feb; (2):CD009012. PubMed ID: 23450595
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Paradoxical immune reconstitution inflammatory syndrome in HIV-infected patients treated with combination antiretroviral therapy after AIDS-defining opportunistic infection.
    Achenbach CJ; Harrington RD; Dhanireddy S; Crane HM; Casper C; Kitahata MM
    Clin Infect Dis; 2012 Feb; 54(3):424-33. PubMed ID: 22095568
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The rate of serious bacterial infections among HIV-infected children with immune reconstitution who have discontinued opportunistic infection prophylaxis.
    Nachman S; Gona P; Dankner W; Weinberg A; Yogev R; Gershon A; Rathore M; Read JS; Huang S; Elgie C; Hudgens K; Hughes W
    Pediatrics; 2005 Apr; 115(4):e488-94. PubMed ID: 15772172
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discontinuation of secondary prophylaxis for opportunistic infections in HIV-infected patients receiving highly active antiretroviral therapy.
    Soriano V; Dona C; Rodríguez-Rosado R; Barreiro P; González-Lahoz J
    AIDS; 2000 Mar; 14(4):383-6. PubMed ID: 10770540
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathogenesis and prevention of immune reconstitution disease during antiretroviral therapy.
    Lawn SD; Meintjes G
    Expert Rev Anti Infect Ther; 2011 Apr; 9(4):415-30. PubMed ID: 21504399
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Time to HAART Initiation after Diagnosis and Treatment of Opportunistic Infections in Patients with AIDS in Latin America.
    Crabtree-Ramírez B; Caro-Vega Y; Shepherd BE; Grinsztejn B; Wolff M; Cortes CP; Padgett D; Carriquiry G; Fink V; Jayathilake K; Person AK; McGowan C; Sierra-Madero J;
    PLoS One; 2016; 11(6):e0153921. PubMed ID: 27271083
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.